Compare Incyte Corporation (INCY) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Wix.Com Ltd — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Wix.Com Ltd trades at $52.25 (market cap $2.23B). The key difference: Incyte Corporation is far larger — about 10.4× Wix.Com Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| INCY | WIX | |
|---|---|---|
Market Cap | $23.11B | $2.23B |
Sector | Health | Technology |
52-Week High | $118.52 | $184.24 |
52-Week Low | $67.38 | $40.43 |
Enterprise Value | $19.13B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Wix trades at $53.34, up 3.67% on the day, with a bearish technical signal and mixed fundamentals. Revenue grew to $1.99B in 2025, but net income fell to $50.65M with a negative margin of -1.97%. The stock faces headwinds from recent earnings misses and legal investigations, yet maintains strong analyst support with a consensus price target of $83.07.
The outlook is cautious due to high valuation multiples and operational risks, but long-term growth potential exists if Wix can leverage AI tools and partnerships to improve profitability. Key risks include competitive pressure and ongoing legal scrutiny, while institutional sentiment remains predominantly bullish.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
